GlaxoSmithKline Pharmaceuticals Limited

NSE GLAXO.NS

GlaxoSmithKline Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2024: 25.69%

GlaxoSmithKline Pharmaceuticals Limited EBITDA Margin is 25.69% for the year ending March 31, 2024, a -7.53% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

GlaxoSmithKline Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2023 was 27.78%, a 7.29% change year over year.
GlaxoSmithKline Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2022 was 25.89%, a 54.64% change year over year.
GlaxoSmithKline Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2021 was 16.74%, a 37.67% change year over year.
GlaxoSmithKline Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2020 was 12.16%, a -47.98% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: GLAXO.NS

GlaxoSmithKline Pharmaceuticals Limited

CEO	Mr. Bhushan Akshikar
IPO Date	July 1, 2002
Location	India
Headquarters	GSK House
Employees	3,211
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Vaccines

Description

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Key trends

Past 5 years